NEVOâ„¢ Sirolimus-Eluting Coronary Stent Yields Superior Results To Taxus(R) Liberte(R) Stent In Pivotal Clinical Trial

At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus® Liberte® Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released . In addition, no reports of stent thrombosis were reported in patients treated with NEVO™ through six months.